Real-world analysis of more than 44,000 patients reinforces safety and effectiveness of Pradaxa in routine clinical care
New data show Pradaxa reduced stroke risk and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation.
Brigham and Women's Hospital in Boston and Boehringer Ingelheim have announced the results of a new interim analysis from a long-term study evaluating the safety and effectiveness of Pradaxa (dabigatran etexilate mesylate) relative to warfarin in routine clinical practice. These data, from a pooled analysis of two large US commercial health insurance databases, showed that patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa — a novel oral anticoagulant (NOAC) — had fewer strokes and fewer major bleeding events compared to NVAF patients treated with warfarin. The findings were presented at the American Heart Association (AHA) Scientific Sessions 2015 in Orlando.
"Beyond clinical trials, there is a wealth of available health insurance data that provides an excellent opportunity to grow our knowledge of oral anticoagulant use and outcomes for patients," said lead investigator John Seeger, Department of Medicine, Brigham and Women's Hospital, a teaching-affiliate of Harvard Medical School. "These real-world data further define the safety and effectiveness of dabigatran for patients and its use in routine care, and are consistent with the results of the pivotal RE-LY clinical trial."
The primary study outcomes were stroke and major bleeding rates during PRADAXA and warfarin treatment, based on data collected over 32 months from 44,672 NVAF patients (22,336 propensity score matched Pradaxa and warfarin treatment initiators) in two insurance databases — Truven MarketScan (18,276 patients per group) and Optum Clinformatics (4,060 patients per group). Researchers identified 65 strokes for Pradaxa-treated patients (0.73 incidence rate per 100 patient years) and 78 strokes for warfarin-treated patients (1.08 incidence rate per 100 patient years), representing a 28% reduction in stroke risk for Pradaxa compared to warfarin (HR 0.72; 95% CI 0.52 - 1.00). In addition, researchers reported 395 major bleeding events for Pradaxa-treated patients (4.47 incidence rate per 100 patient years), compared to 459 events for warfarin-treated patients (6.42 incidence rate per 100 patient years), representing a 26% reduction in the risk of major bleeding events with Pradaxa compared to warfarin (HR 0.74; 95% CI 0.64 - 0.84). There were 238 major gastrointestinal bleeding events for Pradaxa-treated patients (2.69 incidence rate per 100 patient years) and 213 for warfarin treated patients ((2.97 incidence rate per 100 patient years); HR 0.95; 95% CI 0.79 - 1.14).
"With this long-term study program, in collaboration with Brigham and Women's Hospital, we are seeking to expand awareness and understanding of real-world experiences with NOACs and the impact on reducing stroke risk, which remains a major public health concern," said Sabine Luik, senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim. "These data add to the robust research program supporting the real-world value of Pradaxa, the only NOAC with both proven superiority to warfarin in reducing stroke risk in NVAF patients and a specific reversal agent."
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance